A COVID-19 candidate vaccine developed by Beijing-based Sinovac Life Sciences Co., in collaboration with Brazilian research institute Butantan, landed in Brazil. Twelve research centers in six Brazilian states will perform the 9,000 tests on the volunteers in the next 90 days. It is the third and the last stage of testing before distribution.
Copyright © 2020 CGTN. Beijing ICP prepared NO.16065310-3